The newly issued patent includes claims covering both composition of matter of PX-867 and pharmaceutical preparations containing PX-867. The preclinical development for PX-867 has focused on cardiovascular disease. In particular, the compound has demonstrated activity as a coating on intravascular stents in preclinical models of atherosclerotic disease.
Robert Kirkman, president and CEO of Oncothyreon, said: “We intend to seek a partner to develop PX-867 in non-oncology indications, particularly in cardiovascular applications, while focusing our internal development efforts on PX-866 in oncology, our core area of expertise. We expect to file an investigational new drug application for PX-866 in the coming quarter and to initiate a Phase I trial soon thereafter.”